Suppr超能文献

替尼酸及其异构体在人肝微粒体中的羟基化作用和亲电代谢产物的形成。由一种不同于负责美芬妥英羟基化作用的细胞色素P450 IIC催化。

Hydroxylation and formation of electrophilic metabolites of tienilic acid and its isomer by human liver microsomes. Catalysis by a cytochrome P450 IIC different from that responsible for mephenytoin hydroxylation.

作者信息

Dansette P M, Amar C, Valadon P, Pons C, Beaune P H, Mansuy D

机构信息

Unité de Recherche Associée au CNRS (URA 400), Université René Descartes, Paris, France.

出版信息

Biochem Pharmacol. 1991 Feb 15;41(4):553-60. doi: 10.1016/0006-2952(91)90627-h.

Abstract

Tienilic acid (TA) is metabolized by human liver microsomes in the presence of NADPH with the major formation of 5-hydroxytienilic acid (5-OHTA) which is derived from the hydroxylation of the thiophene ring of TA. Besides this hydroxylation, TA is oxidized into reactive metabolites which covalently bind to microsomal proteins. Oxidation of an isomer of tienilic acid (TAI), bearing the aroyl substituent on position 3 (instead of 2) of the thiophene ring, by human liver microsomes, gives a much higher level of covalent binding to proteins. Both covalent binding of TA and TAI metabolites are almost completely suppressed in the presence of glutathione. These three activities of human liver microsomes (TA 5-hydroxylation, covalent binding of TA and TAI metabolites) seem dependent on the same cytochrome P450 of the IIC subfamily, since (i) antibodies against human liver cytochromes P450 IIC strongly inhibit these three activities, (ii) there is a clear correlation between these activities in various human liver microsomes, and (iii) TA acts as a competitive inhibitor for TAI activation into electrophilic metabolites (Ki approximately equal to 25 microM) and TAI inhibits TA 5-hydroxylation. However cross inhibition experiments indicate that tienilic acid hydroxylation and mephenytoin hydroxylation, a typical reaction of some human liver P450 IIC isoenzymes, are not catalysed by the same member of the P450 IIC subfamily.

摘要

替尼酸(TA)在NADPH存在的情况下由人肝微粒体代谢,主要生成5-羟基替尼酸(5-OHTA),它源自TA噻吩环的羟基化。除了这种羟基化反应外,TA还被氧化成可与微粒体蛋白共价结合的反应性代谢产物。人肝微粒体对噻吩环3位(而非2位)带有芳酰基取代基的替尼酸异构体(TAI)进行氧化时,与蛋白的共价结合水平要高得多。在谷胱甘肽存在的情况下,TA和TAI代谢产物的共价结合几乎完全受到抑制。人肝微粒体的这三种活性(TA的5-羟基化、TA和TAI代谢产物的共价结合)似乎依赖于IIC亚家族的同一种细胞色素P450,因为:(i)针对人肝细胞色素P450 IIC的抗体强烈抑制这三种活性;(ii)在各种人肝微粒体中,这些活性之间存在明显的相关性;(iii)TA作为TAI激活生成亲电代谢产物的竞争性抑制剂(Ki约等于25 microM),而TAI抑制TA的5-羟基化。然而,交叉抑制实验表明,替尼酸羟基化和甲妥英羟基化(一些人肝P450 IIC同工酶的典型反应)并非由P450 IIC亚家族的同一种成员催化。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验